“Evolus responds to’I have never spoken to a reporter’ and’I have never paid a dollar per vial'”
“I have never provided any information and confirm that the article is completely unfounded”
[팜뉴스=이권구 기자] Daewoong Pharmaceutical reported on April 4 in a business magazine ‘[단독] Daewoong Pharmaceutical announced on the 5th that it would legally respond to Ebolus with an obvious misinformation.
Daewoong Pharmaceutical said in a statement on the 5th, “Evolus explained Evolus’ 2020 results, current financial status, and future prospects at a conference call on March 24th. “I explained the royalties owed to the plaintiff due to the agreement.”
(With regard to royalties, there are two time periods.The first time period is the 21, at https://earningscast.com/EOLS/20210324, 7 minutes 30 seconds Lauren’s remarks from the Q4 2020 Evolus, Inc. Earnings Conference call at https://earningscast.com/EOLS/20210324. -month period from mid-December 2020 through mid-September 2022.During this time, Evolus will pay a dollar amount per vial sold in the United States.During the same 21-month period, Evolus will also pay a low double-digit royalty on international sales.The impact of which is expected to be nominal through September 2022.The second time period is the 10-year period beginning mid-September 2022.During this time, Evolus will pay a mid single-digit royalty on our global net sales, which is expected to be offset by a nominal US price increase.As such, the settlement economics are not expected to materially impact gross margin after September 2022, which is now only about 17 months away.)
In this regard, Daewoong Pharmaceutical explains that “In other words, the royalties of Ebolus can be divided into 21 months and beyond, and the 21-month portion pays a certain amount compared to the sales volume in the US and the sales outside the United States. From the first sentence, it is clear from the first sentence. Nevertheless, the reporter reported that Daewoong will deliver Nabota to Ebolus for $1 per vial, which is less than the cost, based on the contents of the conference call. What Ebolus mentioned in the conference call is not the delivery cost to be paid to Daewoong, but the royalties payable between Medytox and Aller. Daewoong is supplying Nabota to Ebolus at the regular price, and Ebolus is Daewoong’s at the conference call. “We are not even talking about the supply price,” he argued.
Daewoong Pharmaceutical said in the article’Daewoong Pharmaceutical’s supply of Botox to Ebolus below the cost’,’Delivery to one vial of Nabota, fear of loss in sales of 110 billion won’,’Industry’ , “It seems that the burden is high”, “Evolus has avoided a lot of losses, but Daewoong’s side has been the opposite” are all false facts and obvious misinformations. “Daewoong Pharmaceutical explained to the reporter who wrote the article that the above report was false. He pointed out that he requested political information, but (the newspaper) rejected it, saying it was information received from an anonymous Evolus official.”
Daewoong Pharmaceutical inquired about the facts directly with Evolus, a partner company, and Ebolus said,’I have never spoken to a reporter. I never said that I would pay 1 dollar per vial, and as you know, Ebolus pays a settlement between Medytox and Aller. “We don’t disclose the supply price we pay to either or Daewoong.” In the end, Evolus never provided such information (to the newspaper), and it was confirmed that the article was completely unfounded.” “Therefore, Daewoong Pharmaceutical is planning to respond legally as it judges that it can no longer neglect malicious defamation.”
Copyright © Farm News Unauthorized reproduction and redistribution prohibited